Table 4. AEs of any grade and grade 3−4 in all patients.
| Variables | n (%) | |
| Any grade | Grade 3−4 | |
| AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase. | ||
| Any AEs | 73 (93.6) | 35 (44.9) |
| Any serious AEs | 3 (3.8) | 2 (2.6) |
| AEs leading to discontinuation | 4 (5.1) | 1 (1.3) |
| AEs leading to dose delay/reduction | 3 (3.8) | 2 (2.6) |
| Hematologic toxicities | ||
| Lymphocyte count decreased | 62 (79.5) | 19 (24.4) |
| White blood cell decreased | 54 (69.2) | 20 (25.6) |
| Neutrophil count decreased | 43 (55.1) | 16 (20.5) |
| Anemia | 38 (48.7) | 2 (2.6) |
| Platelet count decreased | 6 (7.7) | 0 (0) |
| Febrile neutropenia | 1 (1.3) | 1 (1.3) |
| Non-hematologic toxicities (≥20% incidence) |
||
| Mucositis oral | 45 (57.7) | 2 (2.6) |
| Diarrhea | 41 (52.6) | 0 (0) |
| Nausea | 38 (48.7) | 0 (0) |
| Constipation | 32 (41.0) | 0 (0) |
| Vomiting | 31 (39.7) | 0 (0) |
| Gastrointestinal pain | 21 (26.9) | 0 (0) |
| Abdominal pain | 17 (21.8) | 0 (0) |
| Malaise | 45 (57.7) | 0 (0) |
| Fatigue | 16 (20.5) | 0 (0) |
| ALT increased | 50 (64.1) | 4 (5.1) |
| AST increased | 43 (55.1) | 5 (6.4) |
| GGT increased | 22 (28.2) | 2 (2.6) |
| Alkaline phosphatase increased | 16 (20.5) | 0 (0) |
| Anorexia | 42 (53.8) | 1 (1.3) |
| Hypoalbuminemia | 19 (24.4) | 0 (0) |
| Dizziness | 33 (42.3) | 0 (0) |
| Insomnia | 20 (25.6) | 0 (0) |
| Hand-foot syndrome | 45 (57.7) | 3 (3.8) |
| Alopecia | 30 (38.5) | 0 (0) |
| Skin hyperpigmentation | 16 (20.5) | 0 (0) |